Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
Bilateral kidney ligation of mice immediately before injection of misonidazole (MIS) prolongs the plasma half-life of this radiosensitizer from about 2 h (in normal mice) to 10-11 h, similar to that in man. Kidney ligation does not, however, change the relative proportions of MIS and its O-demethylated metabolite, Ro-05-9963, for the first 12 h after MIS injection. Kidney ligation was used with the two radiosensitizers, MIS and Ro-05-9963, to investigate the influence of plasma half-life both on peak plasma levels and on the tumour/plasma ratio of sensitizer concentration in the EMT6 mouse tumour. Although the acute LD50 of Ro-05-9963 in normal mice was twice that of MIS, this apparent advantage was offset by peak tumour levels 50% or less of those achieved by equimolar injected doses of MIS. However, by comparing the plasma and tumour levels in mice in which the drug half-lives were prolonged by bilateral kidney ligation, it was concluded that the lower plasma and tumour levels of Ro-05-9963 were a result of its shorter plasma half-life, rather than of an intrinsic barrier to tumour penetration. Because of this rapid clearance, the radiosensitization produced by Ro-05-9963 was less than that produced by equimolar injected doses of MIS. As this difference did not occur in kidney-ligated mice, and hence would not be expected to occur in man, the comparison of MIS and Ro-05-9963 in mice produces an artificially low radiosensitization for Ro-05-9963 and possibly also for other compounds with short plasma half-lives. Although the short plasma half-life of Ro-05-9963 appeared to be responsible for its low peak plasma concentration, it did not produce a low tumour/plasma ratio. Within the limits of plasma nitroimidazole half-lives investigated (0.5-10 h) the tumour/plasma ratio was insensitive to plasma half-life, being 50-70% for both MIS and Ro-05-9963 in both normal and kidney-ligated mice. It is concluded that the common assumption that tumour/plasma ratios of MIS in the mouse are less than those in man is unjustified.
D000818:Animals; D005260:Female; D006207:Half-Life; D007668:Kidney / Q000098:blood supply; D008026:Ligation; D051379:Mice; D008807:Mice, Inbred BALB C; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism*; D009374:Neoplasms, Experimental / Q000097:blood / Q000378:metabolism* / Q000532:radiotherapy; D009392:Nephrectomy; D009593:Nitroimidazoles / Q000031:analogs & derivatives* / Q000378:metabolism*; D011838:Radiation-Sensitizing Agents
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D008920:Misonidazole